Skip to content

Science News About Medications

Rapid Agent Restores Pleasure-seeking Ahead of Other Antidepressant Action

Press Release

Dorsal anterior cingulate cortex

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects.

Continue Reading…

For Schizophrenia, Newer Injectables Not Necessarily Better

Science Update

concerned female woman patient giving info to doctor

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?

Continue Reading…

Webinar on Ketamine and Next Generation Therapies Featuring NIMH’s Carlos A. Zarate, M.D.

Science Update

Carlos A. Zarate, M.D.

On August 13, 2013, Carlos A. Zarate, M.D., from the National Institute of Mental Health will give a live presentation titled “Ketamine & Next Generation Therapies,” where he will discuss his research on novel medications for treatment-resistant depression and bipolar disorder at the Brain and Behavior Research Foundation.

Continue Reading…

NIH Funds Industry Collaborations to Identify New Uses for Existing Compounds

Press Release

NIH logo NCATS colors  thumbnail

NIH Funds Industry Collaborations to Identify New Uses for Existing Compounds

Continue Reading…

Ketamine Cousin Rapidly Lifts Depression Without Side Effects

Science Update

GLX-13 Thumbnail

NMDA or glutamate receptor modulators as antidepressants have come of age. Human clinical studies demonstrated that ketamine can ward off depressive symptoms within 2 hours of administration and last for several days. Yet serious side effects are attached to this drug, including excessive sleepiness, hallucinations, and substance abuse behavior.

Continue Reading…

Long-term Course of ADHD Diagnosed in Preschool Years Can be Chronic and Severe

Science Update

preschool-aged boy

Long-term Course of ADHD Diagnosed in Preschool Years Can be Chronic and Severe

Continue Reading…

Gene Variants Implicated in Extreme Weight Gain Associated with Antipsychotics

Science Update

doctor writing prescription

A small study suggests that people with certain genetic variants may be more susceptible to extreme weight gain if they take certain antipsychotic medications.

Continue Reading…

Brain Signal ID’s Responders to Fast-Acting Antidepressant

Press Release

MEG scan

Biomarkers identified in research on a fast-acting antidepressant can signal who will respond to the medication and are providing clues to how it works to lift depression.

Continue Reading…

Perinatal Antidepressant Stunts Brain Development in Rats

Press Release

abnormal axon

Rats exposed to an antidepressant just before and after birth showed substantial brain abnormalities and behaviors, in a study funded by the National Institutes of Health.

Continue Reading…

Prescribed stimulant use for ADHD continues to rise steadily

Press Release

young boy writing in booklet

The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ).

Continue Reading…

Switching Antipsychotics May Reduce Metabolic Risks

Science Update

Photo of assorted pills.

Patients experiencing cardiovascular or metabolic side effects while taking an antipsychotic medication may fare better if they switch to a different medication provided they are closely monitored, according to an NIMH-funded study.

Continue Reading…

Drug Boosts Growth Factor to Jump-start Rapid Antidepressant Response

Press Release

ketamine mechanism of action

A study in mice has pinpointed a pivotal new player in triggering the rapid antidepressant response produced by ketamine. By deactivating a little-known enzyme, the drug takes the brakes off rapid synthesis of a key growth factor thought to lift depression, say researchers supported by the National Institutes of Health.

Continue Reading…

Rapid Antidepressant Works by Boosting Brain’s Connections

Science Update

neuronal spines on ketamine-treated rat neurons

An experimental drug that lifts depression in hours likely works by rapidly stimulating connections between brain cells, a study in rats has revealed. The drug, called ketamine, quickly generated such synapses in a brain circuit implicated in human depression by triggering a key enzyme.

Continue Reading…

Study Shows Possibilities for Predicting How Patients Will Respond to Antidepressants

Science Update

MRI brain image

In a study of an experimental treatment for major depression, pretreatment testing to probe the function of a specific brain center predicted how patients would respond to ketamine, a medication that can lift depression rapidly in some people.

Continue Reading…

Effects on Personality May Be Mechanism of Antidepressant Effectiveness

Science Update

Silhouetted woman

Results of a study of antidepressant treatment for major depression suggest that changes in personality traits seen in patients taking the drug paroxetine (Paxil) may not be the result of the medication’s lifting of mood but may instead be a direct effect of this class of drugs and part of the mechanism by which they relieve depression.

Continue Reading…

Effectiveness of Long-term Use of Antipsychotic Medication to Treat Childhood Schizophrenia is Limited

Science Update

child playing hopscotch

Few youths with early-onset schizophrenia who are treated with antipsychotic medications for up to a year appear to benefit from their initial treatment choice over the long term, according to results from an NIMH-funded study. The study was published online ahead of print May 4, 2010, in the Journal of the American Academy of Child and Adolescent Psychiatry.

Continue Reading…

Clinical Tests Begin on Medication to Correct Fragile X Defect

Press Release

fragile X chromosome

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder’s neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

Continue Reading…

Significant Weight Gain, Metabolic Changes Associated with Antipsychotic Use in Children

Science Update

medication

Many children and adolescents who receive antipsychotic medications gain a significant amount of weight and experience metabolic changes, according to NIMH-funded research published October 28, 2009, in the Journal of the American Medical Association.

Continue Reading…

Combination Treatment for Psychotic Depression Holds Promise

Science Update

A combination of an atypical antipsychotic medication and an antidepressant known as a selective serotonin reuptake inhibitor (SSRI) may be more effective in treating psychotic depression than an atypical antipsychotic alone, according to results from an NIMH-funded clinical study.

Continue Reading…

Questions Raised About Stimulants and Sudden Death

Science Update

A study examining stimulant use among children and adolescents found an association between stimulants and sudden unexplained death in youth with no evidence of pre-existing heart disease. The finding draws attention to the potential risks of stimulant medication, according to the study’s authors; an accompanying editorial notes that the rarity of sudden unexplained death and the lack of long-term data on the effectiveness of these medications for reducing other health risks make a full benefit/risk assessment difficult.

Continue Reading…

Citalopram No Better Than Placebo Treatment for Children with Autism Spectrum Disorders

Press Release

boy playing with a puzzle

Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.

Continue Reading…

ADHD Medication Treatment Associated with Higher Academic Performance in Elementary School

Science Update

Doctor with young boy

Children with attention deficit hyperactivity disorder (ADHD) who take medication to treat the condition tend to do better in math and reading compared to their peers who also have ADHD but do not take medication, according to data from a national survey. The NIMH-funded study was published in the May 2009 issue of Pediatrics.

Continue Reading…

Use of Antipsychotics in Alzheimer’s Patients May Lead to Detrimental Metabolic Changes

Science Update

Woman looking out a window (photograph).

Atypical antipsychotic medications are associated with weight gain and other metabolic changes among patients with Alzheimer’s disease, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study. The study was published online ahead of print April 15, 2009, in the American Journal of Psychiatry.

Continue Reading…

Premature Birth Risk Higher for Pregnant Women Taking SSRIs or Suffering from Untreated Depression

Science Update

Untreated major depression, as well as the use of antidepressant medications, may increase the risk for premature (preterm) birth, but the risk of other problems in fetuses such as breathing, gastrointestinal, or motor problems, may not be increased, according to a study of pregnant women published online ahead of print March 15, 2009, in the American Journal of Psychiatry.

Continue Reading…

Not All Antipsychotics Created Equal: Analysis Reveals Important Differences

Science Update

An analysis of studies on antipsychotics reveals multiple differences among the newer, second-generation antipsychotics as well as the older medications, and suggests the current classification system blurs important differences, rendering it unhelpful.

Continue Reading…

Cells May Provide Target for New Anxiety Medications

Science Update

A specific population of brain cells could provide a target for developing new medications aimed at helping people learn to mute the fears underlying anxiety disorders, according to NIMH-supported scientists.

Continue Reading…

Symptoms Persist as Bipolar Children Grow Up

Science Update

Bipolar disorder (BD) identified in childhood often persisted into adulthood in the first large follow-up study of its kind.

Continue Reading…

Certain Antipsychotic Medications May Increase Risk for Heart Disease

Press Release

Certain atypical antipsychotic medications may raise the risk for heart disease in people with schizophrenia, according to an analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Continue Reading…

Millisecond Brain Signals Predict Response to Fast-Acting Antidepressant

Press Release

Images of the brains fastest signals reveal an electromagnetic marker that predicts a patients response to a fast-acting antidepressant, researchers have discovered.

Continue Reading…

Newer Antipsychotics No Better Than Older Drug in Treating Child and Adolescent Schizophrenia

Press Release

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health’s National Institute of Mental Health (NIMH).

Continue Reading…

Health Risks Associated with Certain Antipsychotics Warrant Extra Monitoring

Science Update

Some atypical antipsychotics may be more likely than others to cause metabolic and cardiovascular side effects, according to recent analyses using data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

Continue Reading…

Newer Antipsychotics No Better Than Older Medications in Reducing Schizophrenia-related Violence

Science Update

Antipsychotic medications can reduce the risk of violence among people with schizophrenia, but the newer atypical antipsychotics are no more effective in doing so than older medications, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

Continue Reading…

Paying More for Prescriptions May Limit Seniors’ Access to Antidepressants

Science Update

New cost-sharing policies may prevent some older adults diagnosed with depression from filling new antidepressant prescriptions, according to an analysis published in the April 2008 issue of Psychiatric Services.

Continue Reading…

State Survey Finds FDA “Black Box” Warning Correlates with Curtailed Antidepressant Prescriptions

Science Update

After the U.S. Food and Drug Administration (FDA) issued a “black box” warning on antidepressant medications, Nebraskan doctors began prescribing fewer antidepressant medications to children and teens and referring more patients to specialists, according to a state survey. The study, which involved NIMH-funded researchers, was published in the February 2008 issue of the Journal of Child and Adolescent Psychopharmacology.

Continue Reading…

Schizophrenia-Related Gene Linked to Imbalance in Dopamine Pathways

Science Update

Forms of a gene known to increase risk for schizophrenia may create an imbalance in brain pathways for dopamine, suggests a recent study by NIMH scientists.

Continue Reading…

Scientists May Have Found Long-Pursued Binding Site for Antidepressants

Science Update

NIMH-funded scientists have a major new clue as to where the long-pursued binding site for commonly used antidepressants – potentially the site that triggers the medications’ effects – may be on brain cells.

Continue Reading…

Genes Linked to Suicidal Thinking During Antidepressant Treatment

Press Release

Specific variations in two genes are linked to suicidal thinking that sometimes occurs in people taking the most commonly prescribed class of antidepressants, according to a large study led by scientists at the National Institutes of Healths (NIH) National Institute of Mental Health (NIMH).

Continue Reading…

Drops in SSRI prescription rates may coincide with increases in youth suicides

Science Update

A 2004 spike in suicide rates may have coincided with a drop in antidepressant prescriptions for youth, following warnings from U.S and European regulatory agencies that the medications might trigger suicidal thoughts.

Continue Reading…

Manic Phase of Bipolar Disorder Benefits from Breast Cancer Medication

Press Release

The medication tamoxifen, best known as a treatment for breast cancer, dramatically reduces symptoms of the manic phase of bipolar disorder more quickly than many standard medications for the mental illness, a new study shows.

Continue Reading…

Studies Refine Understanding of Treatments for Bipolar Disorder

Science Update

Two new studies provide additional details on best practices for treating people with bipolar disorder, a sometimes debilitating illness marked by severe mood swings between depression and mania.

Continue Reading…

Faster-Acting Antidepressants Closer to Becoming a Reality

Press Release

A new study has revealed more about how the medication ketamine, when used experimentally for depression, relieves symptoms of the disorder in hours instead of the weeks or months it takes for current antidepressants to work.

Continue Reading…

Improvement Following ADHD Treatment Sustained in Most Children

Press Release

Most children treated in a variety of ways for attention deficit hyperactivity disorder (ADHD) showed sustained improvement after three years in a major follow-up study funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH).

Continue Reading…

New Study Will Examine Effects of Excluding Anti-anxiety Medications in Medicare Part D Coverage

Science Update

A new research grant funded by NIMH will examine the costs and benefits of excluding a commonly prescribed class of anti-anxiety medications—benzodiazepines—from coverage in the new Medicare Part D program. Medicare Part D, the prescription drug coverage plan for people insured by Medicare, went into effect in January 2006.

Continue Reading…

Gene Variants Linked to Suicidal Thoughts in Some Men Starting Antidepressant Treatment

Science Update

Some men who experience suicidal thoughts and behaviors after they first start taking antidepressant medications may be genetically predisposed to do so, according to the latest results from the NIMH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study

Continue Reading…

Antipsychotic Medications for Schizophrenia on Equal Footing in Improving Patients’ Thinking Skills

Science Update

Patients with schizophrenia taking antipsychotic medications experience a small improvement in thinking and reasoning skills (neurocognition), but no one medication appears to be better than the others in improving these skills during the first two crucial months of treatment, according to the latest results from the NIMH-funded Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE).

Continue Reading…

Benefits of Antidepressants May Outweigh Risks for Kids

Science Update

The benefits of antidepressant medications likely outweigh their risks to children and adolescents with major depression and anxiety disorders, according to a new comprehensive review of pediatric trials conducted between 1988 and 2006. The study, partially funded by NIMH, was published in the April 18, 2007, issue of the Journal of the American Medical Association.

Continue Reading…

HIV Treatment May Help Reduce Severity of Mental Impairment in Children with HIV Infection

Science Update

During the first few years of life, children born with HIV infection are most susceptible to central nervous system (CNS) disease, and can develop impaired cognitive, language, motor and behavioral functioning. However, NIH-funded researchers have found that among children with HIV infection, treatment with a protease inhibitor (PI)- based highly active antiretroviral therapy (HAART) helped protect against cognitive and motor difficulties compared to a control group of age-matched children who were born to HIV-infected mothers but who did not contract the virus themselves (e.g., HIV-exposed).

Continue Reading…

Global Use of ADHD Medications Rises Dramatically

Science Update

Global use of medications that treat attention deficit/hyperactivity disorder (ADHD) nearly tripled from 1993 to 2003, and spending on the drugs rose nine-fold, according to a study co-funded by NIMH and published in the March/April 2007 issue of Health Affairs.

Continue Reading…

New Details in Schizophrenia Treatment Trial Emerge

Press Release

Two new studies from the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) provide more insights into comparing treatment options, and to what extent antipsychotic medications help people with schizophrenia learn social, interpersonal and community living skills.

Continue Reading…

Weight Gain From Antipsychotics Traced to Appetite-Regulating Enzyme, Receptor

Science Update

A likely mechanism by which antipsychotic medications trigger weight gain — with its attendant risks of heart disease, diabetes and treatment non-adherence — has been unraveled in mice by NIMH-funded scientists.

Continue Reading…

Older Medication May Be More Cost-Effective for Some Patients with Schizophrenia

Press Release

A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia.

Continue Reading…

New NIMH Research Strives to Understand How Antidepressants May Be Associated with Suicidal Thoughts and Actions

Science Update

The National Institute of Mental Health (NIMH), part of the National Institutes of Health, is funding five new research projects that will shed light on antidepressant medications, notably selective serotonin reuptake inhibitors (SSRIs), and their association with suicidal thoughts and actions.

Continue Reading…

U.S. Youth Suicide Rates Lower in Counties with High SSRI Use

Science Update

For children ages five to 14, suicide rates from 1996 to 1998 were lower in areas of the country with higher rates of antidepressant prescriptions, according to an NIMH-funded study published in the November 2006 issue of the American Journal of Psychiatry.

Continue Reading…

Odds of Beating Depression Diminish as Additional Treatment Strategies are Needed

Science Update

An overall assessment of the nation's largest real-world study of treatment-resistant depression suggests that a patient with persistent depression can get well after trying several treatment strategies, but his or her odds of beating the depression diminish as additional treatment strategies are needed.

Continue Reading…

Preschoolers with ADHD Improve with Low Doses of Medication

Press Release

The first long-term, large-scale study designed to determine the safety and effectiveness of treating preschoolers who have attention deficit/hyperactivity disorder (ADHD) with methylphenidate (Ritalin) has found that overall, low doses of this medication are effective and safe.

Continue Reading…

Antipsychotic Medications Used to Treat Alzheimer’s Patients Found Lacking

Press Release

Commonly prescribed antipsychotic medications used to treat Alzheimer’s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by NIMH.

Continue Reading…

NIMH Researchers Discover Medication’s Antidepressant Potential

Science Update

A commonly used sedative and motion-sickness treatment shows promise as a fast-acting antidepressant, according to a study conducted by researchers at NIMH.

Continue Reading…

New Schizophrenia Trial: Does Method of Administering Medication Make a Difference?

Science Update

A new clinical trial is testing whether an injection of a long-lasting antipsychotic medication every two weeks results in better adherence to treatment and better outcomes among people with schizophrenia than do oral medications taken daily.

Continue Reading…

Subsequent Treatment Strategies for Persistent Depression Yield Modest Results

Science Update

Patients with treatment-resistant depression had a modest chance of becoming symptom-free when they tried different treatment strategies after two or three failed treatments, according to results from the nation's largest real-world study of depression.

Continue Reading…

Experimental Medication Kicks Depression in Hours Instead of Weeks

Press Release

People with treatment—resistant depression experienced symptom relief in as little as two hours with a single intravenous dose of ketamine, a medication usually used in higher doses as an anesthetic in humans and animals, in a preliminary study.

Continue Reading…

Switching to a Third Antidepressant Medication May Prove Helpful to Some with Treatment-Resistant Depression

Science Update

The next wave of results from the nation's largest real-world study of treatment-resistant depressionshows that patients had a moderate chance of becoming symptom-free when they switched to a third antidepressant medication, following two previously unsuccessful medication attempts.

Continue Reading…

Antipsychotic Prescriptions Rise Sharply for Children and Adolescents

Science Update

The number of antipsychotic medication prescriptions for children and adolescents increased six-fold from 1993 to 2002, according to a study of visits made by people 20 years old and younger to doctors' offices.

Continue Reading…

Antidepressant Does Not Reduce Risk Of Relapse Among Patients With Anorexia Nervosa

Science Update

An NIMH-funded study has concluded that the antidepressant medication fluoxetine (Prozac) is no more effective than placebo in preventing relapse among patients with anorexia nervosa who had achieved a healthy weight during inpatient or day-program treatment.

Continue Reading…

Depression Rates Are Lower in Children Whose Mothers Are Successfully Treated

Science Update

When women treated for depression become symptom-free, their children are less likely to be diagnosed with depression, according to a study published in the March 22/29 issue of the Journal of the American Medical Association.

Continue Reading…

Studies Offer New Information About Treatment Choices for Schizophrenia — Phase 2 Results

Science Update

A national clinical trial comparing clozapine with other new-generation antipsychotic medications for the treatment of chronic schizophrenia has shown that people who switched to clozapine from their first medication because it failed to manage symptoms adequately were twice as likely to continue treatment as patients who switched to other antipsychotic medications.

Continue Reading…

New Strategies Help Depressed Patients Become Symptom-Free

Press Release

Results of the nation’s largest depression study show that one in three depressed patients who previously did not achieve remission using an antidepressant became symptom-free with the help of an additional medication and one in four achieved remission after switching to a different antidepressant.

Continue Reading…

Maintenance Treatment Prevents Recurrence in Older Adults with Single-Episode Depression

Press Release

People age 70 and older who continued taking the antidepressant that helped them to initially recover from their first episode of depression were 60 percent less likely to experience a new episode of depression over a two-year study period than those who stopped taking the medication, according to a study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health.

Continue Reading…

Gene Influences Antidepressant Response

Press Release

Whether depressed patients will respond to an antidepressant depends, in part, on which version of a gene they inherit, a study led by scientists at NIH has discovered. Having two copies of one version of a gene that codes for a component of the brain’s mood―regulating system increased the odds of a favorable response to an antidepressant by up to 18 percent, compared to having two copies of the other, more common version.

Continue Reading…

Lithium Blocks Enzyme To Help Cells’ Clocks Keep On Tickin’

Science Update

NIMH-funded researchers have discovered how lithium likely fixes body clocks gone awry, stabilizing sleep-wake cycles and other daily rhythms disturbed along with mood in bipolar disorder.

Continue Reading…

Mice Lacking Social Memory Molecule Take Bullying in Stride

Press Release

The social avoidance that normally develops when a mouse repeatedly experiences defeat by a dominant animal disappears when it lacks a gene for a memory molecule in a brain circuit for social learning, scientists funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) have discovered.

Continue Reading…

Stopping Antidepressant Use While Pregnant May Pose Risks

Science Update

Pregnant women who discontinue antidepressant medications may significantly increase their risk of relapse during pregnancy, a new NIMH-funded study has found.

Continue Reading…

Initial Results Help Clinicians Identify Patients with Treatment-Resistant Depression

Press Release

Initial results of the nation’s largest clinical trial for depression have helped clinicians to track “real world” patients who became symptom-free and to identify those who were resistant to the initial treatment.

Continue Reading…

Nobelist Discovers Antidepressant Protein in Mouse Brain

Press Release

A protein that seems to be pivotal in lifting depression has been discovered by a Nobel Laureate researcher funded by NIMH.

Continue Reading…

NIMH Study To Guide Treatment Choices for Schizophrenia (Phase 1 Results)

Press Release

A large study funded by NIH's National Institute of Mental Health (NIMH) provides, for the first time, detailed information comparing the effectiveness and side effects of five medications — both new and older medications — that are currently used to treat people with schizophrenia.

Continue Reading…

Actor-Patients´ Requests for Medications Boost Prescribing for Depression

Press Release

Researchers funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, have found that requests from patients for medications have a "profound effect" on physicians prescribing for major depression and adjustment disorder.

Continue Reading…

New Neurons Born in Adult Rat Cortex

Press Release

Recent evidence suggesting that antidepressants may act by triggering the birth of new neurons in the adult hippocampus,* the brain's memory hub, has heightened interest in such adult neurogenesis and raised the question: Could new neurons also be sprouting up in the parts of the adult brain involved in the thinking and mood disturbances of depression and anxiety?

Continue Reading…

Mutant Gene Linked to Treatment-Resistant Depression

Science Update

A mutant gene that starves the brain of serotonin, a mood-regulating chemical messenger, has been discovered and found to be 10 times more prevalent in depressed patients than in control subjects, report researchers funded by the National Institutes of Health’s National Institute of Mental Health (NIMH) and National Heart Lung and Blood Institute (NHLBI).

Continue Reading…

Psychotherapy, Medications Best for Youth With Obsessive Compulsive Disorder

Press Release

Children and adolescents with Obsessive Compulsive Disorder (OCD) respond best to a combination of both psychotherapy and an antidepressant, a major clinical trial has found.

Continue Reading…

Combination Treatment Most Effective in Adolescents with Depression

Press Release

A clinical trial of 439 adolescents with major depression has found a combination of medication and psychotherapy to be the most effective treatment.

Continue Reading…

Research to Test Treatment of Cognitive Dysfunction in Schizophrenia

Press Release

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Continue Reading…

“Care Managers” Help Depressed Elderly Reduce Suicidal Thoughts

Press Release

An intervention that includes staffing doctors’ offices with depression care managers helps depressed elderly patients reduce suicidal thoughts, a study funded by NIH’s National Institute of Mental Health (NIMH) has found.

Continue Reading…

Creation of New Neurons Critical to Antidepressant Action in Mice

Press Release

Blocking the formation of neurons in the hippocampus blocks the behavioral effects of antidepressants in mice, say researchers funded by the National Institutes of Health (NIH).

Continue Reading…

Medication and Psychotherapy Treat Depression in Low-Income Minority Women

Press Release

Treatment with medication or psychotherapy reduced depressive symptoms in women from minority populations, according to research funded by the National Institute of Mental Health (NIMH).

Continue Reading…

Lithium Shows Promise Against Alzheimer’s in Mouse Model

Press Release

An enzyme crucial to formation of Alzheimer’s plaques and tangles may hold promise as a target for future medications, suggest studies in mice and cells.

Continue Reading…

Brain Shrinkage in ADHD Not Caused by Medications

Press Release

A 10-year study by National Institute of Mental Health (NIMH) scientists has found that brains of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) are 3-4 percent smaller than those of children who don't have the disorder—and that medication treatment is not the cause.

Continue Reading…

Attention Deficit/Hyperactivity Disorders: Are Children Being Overmedicated?

Press Release

NOTE TO WRITERS AND EDITORS: Dr. Richard Nakamura, Acting Director of the National Institute of Mental Health, testified this morning before the Committee on Government Reform, United States House of Representatives.

Continue Reading…

NIMH Study Finds Anti-Psychotic Medication Useful in Treating Serious Behavioral Problems among Children with Autism

Press Release

One of a newer class of anti-psychotic medications was successful and well tolerated for the treatment of serious behavioral disturbances associated with autistic disorder in children ages 5 to 17.

Continue Reading…

Drug Targets Brain Circuits that Drive Appetite and Body Weight

Press Release

Research conducted in animals has revealed that an appetite suppressant drug, D-fenfluramine (D-FEN), activates brain pathways that regulate food intake and body weight.

Continue Reading…

Placebo, Antidepressant May Lift Depression Via Common Mechanism

Press Release

Whether it's a widely prescribed medication or a placebo, a successful treatment for depression must trigger a common pattern of brain activity changes, suggests a team of researchers funded by the National Institute of Mental Health.

Continue Reading…